Search Medical Condition
Please enter condition
Please choose location from dropdown

Northbrook, Illinois Clinical Trials

A listing of Northbrook, Illinois clinical trials actively recruiting patient volunteers.

RESULTS

Found (369) clinical trials

Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis

Objectives To define the cellular and molecular biomarkers of atopic dermatitis in skin biopsies and blood samples from a pre-adolescent pediatric population and correlate it with disease severity. To measure the skin barrier in atopic dermatitis. To determine quality of life in atopic dermatitis through various questionnaires. Objectives for the …

Phase N/A

0.0 miles

Learn More »

Hybrid L24 New Enrollment Post Approval Study

This study evaluates the long term safety and effectiveness of the Nucleus Hybrid L24 Implant in a group of newly implanted adults.

Phase N/A

0.0 miles

Learn More »

Memory Gel and Shape Combined Cohort

The post-approval study will include 2518 women undergoing breast augmentation or reconstruction with MemoryShape or MemoryGel Breast Implants. Four cohorts will be included: primary augmentation, revision-augmentation, primary reconstruction, and revision-reconstruction. For the purpose of assessing rheumatological and neurological signs and symptoms, a control group of 300 women will be selected …

Phase N/A

0.0 miles

Learn More »

Long Term Safety and Efficacy Study of SAR442168 in Participants With Relapsing Multiple Sclerosis

Approximately 62 months including the 8 weeks post-treatment visit

Phase

0.0 miles

Learn More »

Long-term Safety Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS study. Vaccination sub-study The purpose of this research sub-study is to find out the effects of ofatumumab on the development of antibody …

Phase

0.0 miles

Learn More »

Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)

This is a multicenter, longitudinal, single-arm, open-label study to describe the change from baseline in cognitive processing speed, measured by the SDMT, in subjects with RMS treated with ozanimod HCl 1 mg at 3 years. All subjects will receive orally administered ozanimod HCl 1 mg. The primary efficacy endpoint is …

Phase

0.0 miles

Learn More »

A Study to Asses Efficacy Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS

A total of 960 subjects are planned to be randomized into this study to receive treatment with GA Depot or with matching placebo. During the placebo controlled period (PC period, the first 52 weeks of the study immediately after randomization) subjects will receive either 40mg of GA Depot or matching …

Phase

0.0 miles

Learn More »

Safety and Tolerability of Conversion From Oral Injectable or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients.

This is a 6-month, open-label, multi-center, single arm design, including 300-400 advancing RMS patients, evaluating overall safety and tolerability profile when acutely converting to siponimod (Mayzent) from oral, injectable or infusion RMS DMT.

Phase

0.91 miles

Learn More »

Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer

DUAL PRIMARY OBJECTIVE: I. To determine disease free survival (DFS) and overall survival (OS) in all patients with muscle-invasive bladder and upper-tract urothelial carcinoma treated with adjuvant pembrolizumab (MK-3475) versus (vs.) observation. SECONDARY OBJECTIVES: I. To determine DFS and OS in PD-L1 positive and negative patients with muscle-invasive bladder and …

Phase

2.65 miles

Learn More »

Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension

This is a multi-site, placebo-controlled, double-blind, randomized withdrawal, time to intervention study with a duration of up to 36 weeks, consisting of 5 periods: Screening Period: up to 4 weeks duration; Open-Label Titration Period (Titration Period): up to 4 weeks duration; Open-Label Treatment Period (Open-Label Period): 12 weeks duration; Double-Blind …

Phase

2.65 miles

Learn More »